Arcturus Therapeutics Holdings Inc. (ARCT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Arcturus Therapeutics Holdings Inc. (ARCT) Healthcare & Pipeline Overview

Arcturus Therapeutics Holdings Inc. is a biotechnology firm specializing in RNA medicines, utilizing its LUNAR delivery platform to develop innovative vaccines and therapies for infectious diseases, rare liver conditions, and respiratory ailments, positioning it within the competitive landscape of mRNA-based drug development.

What Is the Investment Thesis for ARCT?

Arcturus Therapeutics presents a compelling, albeit high-risk, investment opportunity within the RNA therapeutics space. The company's proprietary LUNAR delivery platform is a key value driver, enabling targeted delivery of mRNA therapies. Upcoming clinical trial results for LUNAR-OTC and LUNAR-CF programs will be critical catalysts. The company's collaborations with Janssen, Ultragenyx, and CureVac provide validation and potential revenue streams. However, the company’s negative profit margin of -88.7% and a P/E ratio of -2.10 highlights the financial risks associated with biotechnology companies that are still in the development stage. The high beta of 2.49 indicates significant volatility. Success hinges on positive clinical outcomes and effective commercialization strategies.

Based on FMP financials and quantitative analysis

ARCT Key Highlights

Market capitalization of $382M reflects investor valuation of Arcturus's pipeline and technology.

• Gross margin of 94.6% indicates strong potential profitability upon successful commercialization of products.
• Free cash flow of $0.01 billion provides financial flexibility for ongoing research and development activities.
• Negative profit margin of -88.7% highlights the current lack of product revenue and high R&D expenses.
• Beta of 2.49 suggests the stock is significantly more volatile than the overall market.

Who Are ARCT's Competitors?

ARCT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ARCT's Key Strengths?

Proprietary LUNAR delivery platform.

• Strong intellectual property portfolio.
• Strategic collaborations with leading pharmaceutical companies.
• Focus on high-growth RNA therapeutics market.

What Are ARCT's Weaknesses?

Limited product revenue and reliance on collaborations.

• High R&D expenses and negative profit margin.
• Dependence on clinical trial outcomes.
• Smaller size compared to major pharmaceutical companies.

What Could Drive ARCT Stock Higher?

Clinical trial results for LUNAR-OTC program in 2026 will be a key catalyst.

• Data readout from LUNAR-CF clinical trials in late 2026 could drive stock appreciation.
• Progress in collaborations with Janssen, Ultragenyx, and CureVac will provide ongoing catalysts.
• Regulatory approvals for LUNAR-COV19 vaccine in various markets could boost revenue.

What Are the Key Risks for ARCT?

Financial-distress signal — its Altman Z-Score of -0.46 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-36.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures could negatively impact the stock price.
• Competition from larger pharmaceutical companies with greater resources.
• Regulatory hurdles and delays in product approvals.
• Dependence on collaborations and partnerships for funding and expertise.
• Market volatility and economic downturns could affect investor sentiment.

What Are the Growth Opportunities for ARCT?

• LUNAR-OTC Program: The LUNAR-OTC program targets ornithine transcarbamylase (OTC) deficiency, a rare genetic disorder. The market for OTC deficiency treatments is estimated to grow as awareness and diagnostic capabilities improve. Positive clinical trial results and regulatory approval could drive significant revenue growth for Arcturus. The timeline for potential commercialization is dependent on clinical trial outcomes, with potential launch in the next 3-5 years.
• LUNAR-CF Program: The LUNAR-CF program focuses on developing mRNA therapeutics for cystic fibrosis (CF) lung disease. The CF market is substantial, with ongoing demand for improved treatments. Arcturus's approach aims to address CF caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Successful development and commercialization could capture a significant share of this market within the next 5 years.
• LUNAR-COV19 Vaccine: Arcturus is developing the LUNAR-COV19 vaccine, leveraging its mRNA technology to combat COVID-19. While the COVID-19 vaccine market is becoming increasingly competitive, there remains a need for improved and variant-specific vaccines. Arcturus's vaccine could gain traction through strategic partnerships and differentiation based on efficacy and safety profiles. The timeline for further development and potential market entry is ongoing, contingent on regulatory approvals and market demand.
• Partnerships and Collaborations: Arcturus has established collaborations with leading pharmaceutical and biotechnology companies, including Janssen, Ultragenyx, and CureVac. These partnerships provide access to resources, expertise, and potential revenue streams. Expanding and strengthening these collaborations will be crucial for driving growth and diversifying Arcturus's pipeline. Ongoing collaborations are expected to yield further developments in the next 2-3 years.
• Expansion into New Therapeutic Areas: Arcturus has the potential to expand its RNA medicines platform into new therapeutic areas beyond infectious diseases, rare liver conditions, and respiratory ailments. This could include developing treatments for cancer, cardiovascular diseases, and other chronic conditions. Successful expansion would significantly broaden Arcturus's market opportunity and drive long-term growth. This strategic diversification could unfold over the next 5-7 years.

What Are ARCT's Competitive Advantages?

• Proprietary LUNAR delivery platform for targeted RNA delivery.
• Strong intellectual property portfolio protecting its technologies.
• Established collaborations with leading pharmaceutical companies.
• Expertise in mRNA-based drug development and manufacturing.

What Does ARCT Do?

Founded in 2013 and headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. is an RNA medicines company dedicated to creating novel therapeutics and vaccines. The company's core focus is on leveraging its proprietary LUNAR delivery platform, which enables the efficient and targeted delivery of RNA-based medicines to specific tissues and cells within the body. Arcturus's pipeline includes development programs targeting ornithine transcarbamylase (OTC) deficiency (LUNAR-OTC), cystic fibrosis (LUNAR-CF), COVID-19 (LUNAR-COV19), and influenza (LUNAR-FLU). These programs aim to address significant unmet medical needs in infectious diseases, rare liver conditions, and respiratory ailments. Arcturus collaborates with several leading pharmaceutical and biotechnology companies, including Vinbiocare Biotechnology Joint Stock Company, Janssen Pharmaceuticals, Ultragenyx Pharmaceutical, CureVac AG, Singapore Economic Development Board, Duke-NUS Medical School, and Millennium Pharmaceuticals, Inc. These partnerships focus on developing nucleic acid-based therapeutics and vaccines for various indications, including hepatitis B virus, rare diseases, COVID-19, and non-alcoholic steatohepatitis. Arcturus's commitment to innovation and strategic collaborations positions it as a key player in the rapidly evolving field of RNA medicines.

What Products and Services Does ARCT Offer?

• Develops RNA medicines for infectious diseases.
• Creates therapies for rare liver conditions like ornithine transcarbamylase (OTC) deficiency.
• Focuses on treatments for respiratory ailments, including cystic fibrosis.
• Utilizes its proprietary LUNAR delivery platform for targeted drug delivery.
• Develops mRNA vaccines for COVID-19 and influenza.
• Collaborates with pharmaceutical companies to expand its pipeline.

How Does ARCT Make Money?

• Develops and licenses its RNA medicine technologies.
• Generates revenue through research and development collaborations.
• Aims to commercialize its own pipeline of therapeutics and vaccines.
• Out-licenses its LUNAR delivery platform to other companies.

What Industry Does ARCT Operate In?

Arcturus Therapeutics operates within the rapidly expanding RNA therapeutics market, driven by advancements in mRNA technology and targeted drug delivery systems. The market is characterized by intense competition among companies developing novel therapies for a wide range of diseases. Key trends include the increasing adoption of mRNA vaccines, the development of personalized medicines, and the growing demand for effective treatments for rare diseases. Arcturus's LUNAR delivery platform positions it to compete effectively in this market, but it faces challenges from larger, more established players with greater resources.

Who Are ARCT's Key Customers?

• Pharmaceutical and biotechnology companies through collaborations.
• Patients with infectious diseases, rare liver conditions, and respiratory ailments.
• Government agencies and non-profit organizations for vaccine development.
• Healthcare providers who administer Arcturus's therapies and vaccines.

Wall Street analysts project Arcturus Therapeutics Holdings Inc. revenue of about $15.3M for fiscal 2026, with EPS near $-4.03. The estimate reflects 10 contributing analysts.

Arcturus Therapeutics Holdings Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.46 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Arcturus Therapeutics Holdings Inc. stands at -36.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -32.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -26.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -35.0%, the inverse of the P/E and a quick read on earnings relative to price.

Arcturus Therapeutics Holdings Inc. (ARCT) Valuation Context

Valued at $382M, ARCT is classified as a small-cap stock. Relative to its peer group, ARCT's quantitative score of 14/100 is below the peer average of 65/100.

ARCT Revenue & Earnings Trend

In Q2 2026, ARCT generated $3.0M in top-line revenue, marking a sequential increase of 385.1%. The company recorded a net loss of $23.8M, with diluted EPS of $-0.84. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ARCT averaged $-0.83 in diluted EPS.

Company Profile

Arcturus Therapeutics Holdings Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Joseph E. Payne. ARCT has traded publicly since 2013.

ARCT Financials

ARCT Latest News

ARCT Analyst Consensus

ARCT MoonshotScore

ARCT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources